Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 2Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Spinocerebellar Degenerations 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Carcinoma, Non-Small-Cell Lung 2Vascular Complications 1Solid Tumors 1Solid Cancers 1Small Cell Lung Carcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Locally Advanced Rectal Cancer 1Hypersensitivity 1Head and Neck Neoplasms 1Gynecologic Cancers 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Immune Checkpoint Inhibitors × Clear all
NCT07277777 2026-01-06

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Jinan Military General Hospital

Phase 2 Not yet recruiting
90 enrolled

Neoplasms, Recurrence

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡